[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cognition-disorders\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cognition-disorders":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,47,82,105,129,143,168,200,231,257],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100641365","moderate-intensity-aerobic-calisthenics-for-rural-elderly-with-motoric-cognitive-risk-syndrome-100641365",false,"NCT07658469","Moderate-Intensity Aerobic Calisthenics for Rural Elderly With Motoric Cognitive Risk Syndrome","A Study on the Application of Moderate-Intensity Aerobic Calisthenics in Rural Elderly With Motoric Cognitive Risk Syndrome","Inclusion Criteria:\n\n* Age ≥60 years;\n\n  * Meeting the diagnostic criteria for Motor Cognitive Risk Syndrome (MCR);\n\n    * Clear consciousness and ability to communicate clearly;\n\n      * Permanent residents of rural areas in nine prefecture-level cities of Fujian Province (with an annual residence of ≥9 months) and no plan to relocate within the next year; -⑤ Willing to voluntarily participate and sign the informed consent form.\n\nExclusion Criteria:\n\n* Presence of severe mental disorders, history of stroke, Parkinson's disease, or severe visual\u002Fauditory impairments;\n\n  * Physical disability that prevents independent walking;\n\n    * Comorbid severe systemic diseases, such as cardiopulmonary conditions; -④ Regular exercise habits within the past 6 months (≥30 minutes\u002Fday, ≥3 days\u002Fweek) or a long-term history of exercise; -⑤ Current participation in other interventional studies.",true,"ALL","60 Years",{"count":20,"type":21},106,"ESTIMATED","INTERVENTIONAL",[24],"NA","The aging of China's rural population is severe, with both the prevalence and mortality rates of dementia higher in rural areas than in urban areas. Motor Cognitive Risk Syndrome (MCR), as a novel pre-dementia syndrome characterized by both subjective cognitive decline and slow gait, represents a \"golden window of opportunity\" for the early prevention and treatment of dementia. Currently, there is no specific pharmacological treatment for MCR; non-pharmacological interventions, particularly exercise interventions, are key strategies. Moderate-intensity aerobic calisthenics, which integrates music, dance, and gymnastic elements, is economical, simple, highly engaging, safe, and has demonstrated potential for improving both cognitive and gait function, making it especially suitable for promotion in resource-limited rural settings. However, there is a lack of systematic, theory-guided exercise intervention protocols and effectiveness validation for rural older adults with MCR. Therefore, this study aims to develop and validate a moderate-intensity aerobic calisthenics intervention protocol tailored to this population.",[27,28],"Cognition Disorders","Aged",[30,31,32,33,28],"MCR","Motoric Cognitive Risk Syndrome","moderate-intensity aerobic exercise","rural areas","NOT_YET_RECRUITING","2026-06-14",{"date":37,"type":38},"2026-06-22","ACTUAL",{"date":40,"type":21},"2026-07-01",{"date":42,"type":21},"2027-01-31",{"name":44,"class":45},"Fujian Provincial Hospital","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":58,"briefSummary":59,"conditions":60,"keywords":65,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":46},"100633442","brain-stimulation-and-cognitive-training-for-mci-100633442","NCT07526740","Brain Stimulation and Cognitive Training for MCI","Combining Brain Stimulation With Computerized Cognitive Training for MCI","RISE pilot","Inclusion Criteria:\n\n1. Age 60-85 (inclusive).\n2. English as a first\u002Fprimary language.\n3. Adequate sensorimotor function and verbal expressive abilities to complete all assessments.\n4. Must have a co-participant (e.g. spouse, adult child or relative, sibling, cohabitator, friend, caregiver) who has at least weekly in-person contact with the participant and is willing to participate in the study as a collateral informant.\n5. Meets the following requirements for current and prior medications and treatments:\n\n   1. Is on fixed pharmacotherapy (i.e. stable dose of medication\u002Fs) for ≥ 4 weeks before enrollment. This includes, but is not limited to, cholinesterase inhibitors, NMDA receptor antagonists, and antidepressants.\n   2. Anti-amyloid monoclonal antibody therapy for AD\u002FMCI:\n\n      * Prior treatment is permitted if last infusion occurred ≥ 8 weeks before enrollment.\n      * Current treatment is permitted if the dose has been stable for ≥ 12 weeks before enrollment, with no planned dose change during study participation.\n   3. Prior TMS treatment is permitted if the last stimulation session was ≥ 24 weeks before enrollment.\n6. Documented diagnosis of MCI per NIA-AA criteria or Mild Neurocognitive Disorder per DSM-5 criteria by a healthcare provider within the past year, with a presumed etiology of possible or probable AD 7. Met actuarial neuropsychological criteria for MCI43 within the past year (i.e. ≥2 impaired scores within one cognitive domain, or ≥1 impaired scores in ≥3 domains, where an impaired score is defined as ≤16th percentile using appropriate demographically-corrected norms).\n\nExclusion Criteria:\n\n1. Telephone Interview for Cognitive Status (TICS) score of ≤ 22 suggestive of dementia.\n2. Prior diagnosis of Dementia (NIA-AA) or Major Neurocognitive Disorder (DSM-5).\n3. Daily\u002Fweekly anticholinergic or sedative use. Stimulants may be allowed pending investigator review.\n4. History of significant or unstable condition\u002Fs or treatments for these condition\u002Fs that may impact cognition (as determined by the study investigators) such as significant cardiac (e.g. heart failure), infectious (e.g. HIV, urinary tract infection), or metabolic disease (e.g. labile diabetes), cancer (e.g. brain cancer, chemotherapy-induced cognitive impairment), severe mental illness (e.g., bipolar disorder, psychoses), alcohol or substance use disorder, developmental disorder (e.g. autism spectrum disorder, intellectual disability), or other neurologic disease (e.g. movement disorder, multiple sclerosis, moderate to severe brain injury, seizures).\n5. Plan to initiate treatment for AD\u002FMCI with monoclonal antibody therapy during study participation.\n6. For those currently receiving monoclonal antibody therapy, documented history of clinically significant amyloid-related imaging abnormalities (ARIA) in their medical record.\n7. Current use of any implanted brain stimulation device.\n8. Enrolled in a clinical trial or has received an investigational medication or device in the last 30 days that may impact cognition or mood.\n9. MRI contraindications (e.g., ferromagnetic implants, claustrophobia).\n10. Unable or unwilling to engage in BrainHQ activities.\n11. TMS contraindications (e.g., ferromagnetic implants, conditions or treatments that lower seizure threshold, taking medications that have short half-lives) or no identifiable motor threshold.","85 Years",{"count":57,"type":21},50,[24],"This is a randomized clinical trial of a treatment that combines non-invasive brain stimulation with computerized cognitive training (CCT) for people with mild cognitive impairment (MCI). The form of brain stimulation used in this study is accelerated intermittent theta burst stimulation (iTBS). All participants receive the same amount of iTBS and are randomly assigned to engage in one of two types of CCT. The goals of the study are to see if this combined treatment is feasible and acceptable to people with MCI and whether combined iTBS and CCT improves memory, thinking skills, mood, and daily function.",[61,62,63,64,27],"Mild Cognitive Impairment (MCI)","Mild Neurocognitive Disorder","Neurocognitive Disorders","Cognitive Dysfunction",[66,67,68,69,70,71],"Aging","Alzheimers","Memory Loss","Mild Cognitive Impairment","Transcranial Magnetic Stimulation","cognitive training","RECRUITING","2026-05-20",{"date":75,"type":38},"2026-05-22",{"date":77,"type":38},"2026-03-16",{"date":79,"type":21},"2030-05-31",{"name":81,"class":45},"Medical University of South Carolina",{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":88,"eligibilityCriteria":89,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":90,"enrollmentInfo":91,"targetDuration":4,"studyType":22,"phases":93,"briefSummary":94,"conditions":95,"keywords":4,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":46},"100580372","impact-of-glasses-for-vision-problems-on-cognitive-function-in-rural-older-adults-100580372","NCT06836440","Impact of Glasses for Vision Problems on Cognitive Function in Rural Older Adults","The Impact of Spectacle Intervention for Refractive Error and Presbyopia on Cognitive Function in Rural Older Adults","CLEVER","Inclusion Criteria:\n\n* Older adults who meet all of the following criteria will be eligible to participate in this study:\n\n  * Registered as a rural resident (holding rural household registration);\n  * Age from 60 to 79 years at the time of enumeration;\n  * Resident in the household for \\> = 3 months and planning to reside in the local area for the trial duration;\n  * Distance vision impairment (VI, presenting visual acuity \\[VA\\] \\\u003C 6\u002F12 in the better-seeing eye and improving to ≥ 6\u002F7.5 or better in either eye with spectacle correction) and\u002For near VI (presenting near VA \\\u003C 6\u002F12 at 40 cm when measured binocularly and improving to ≥ 6\u002F7.5 or better in either eye with near correction);\n  * Independent mobility with or without the support of a walking stick;\n  * Chinese version of the Mini-Mental State Examination (C-MMSE) score above the following cut-offs (out of 30): \\>17 for illiterate participants, \\>20 for those with primary school education, \\>22 for those with junior high school education, and \\>23 for those with high school education or above.\n  * Willingness to participate, to be randomized to either study group, and to adhere to the protocol\n\nExclusion Criteria:\n\n* Presence of glaucoma or visually significant cataract, or a history of surgical treatment for these or other major ocular conditions;\n* Consistent use of prescription spectacles and\u002For hearing aids;\n* Serious medical illness likely to result in loss to follow-up. Those less severely affected by conditions such as hypertension and\u002For diabetes will be eligible;\n* Failure on the whispered voice hearing screening test in the better ear (unable to repeat \\> = 3 out of 6 words whispered from behind the participant at a distance of 50 cm);","79 Years",{"count":92,"type":21},964,[24],"The aim of this project is to explore whether vision correction can effectively slow cognitive decline in older adults.\n\nThe primary question it seeks to answer is: Can providing free near and\u002For distance vision correction glasses to older adults with refractive errors or uncorrected vision, who have normal baseline cognition and hearing, reduce the rate of cognitive decline over 36 months in a cost-effective manner? Researchers will compare the rate of cognitive decline over 36 months between older adults who receive refractive correction and those who do not.",[27],"2026-05-12",{"date":98,"type":38},"2026-05-14",{"date":100,"type":38},"2025-11-10",{"date":102,"type":21},"2030-12-31",{"name":104,"class":45},"Yuju Wu",{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":4,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":17,"minAge":112,"maxAge":113,"enrollmentInfo":114,"targetDuration":4,"studyType":22,"phases":116,"briefSummary":117,"conditions":118,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":46},"100637037","the-effect-of-tdcs-combined-with-tms-on-cognitive-impairment-and-motor-function-after-stroke-100637037","NCT07573475","The Effect of tDCS Combined With TMS on Cognitive Impairment and Motor Function After Stroke","The Effect of Transcranial Electrical Stimulation Combined With Transcranial Magnetic Stimulation on Cognitive Impairment and Motor Function After Stroke","Inclusion Criteria:\n\n* Meeting the diagnostic criteria for hemorrhagic or ischemic stroke in the Chinese Guidelines for the Prevention and Treatment of Cerebrovascular Diseases(2nd edition), with the first onset, single hemisphere stroke, and confirmed by CT or MRI,course of diease 1-6 months;\n* Age ranging from 30 to 80 years old;\n* Native language is Mandarin or Cantonese;\n* Right-handed;\n* Diagnosed with post-stroke cognitive impairment(PSCI) by the MoCA scale;\n* Able to cooperate in completing the speech repetition test;\n* Normal hearing.\n\nExclusion Criteria:\n\n* Currently receiving non-invasive brain stimulation treatment;\n* Lesions involving the left DLPFC brain regions;\n* History of epilepsy, mental illness,or other neurological or mental disorders;\n* Any contraindications for transcranial electrical stimulation.","30 Years","80 Years",{"count":115,"type":21},24,[24],"This clinical trial aims to investigate whether transcranial electrical stimulation (tDCS) combined with transcranial magnetic stimulation(TMS) has an impact on the cognitive and motor functions of stroke patients, and to evaluate the safety of this protocol. The main objective is to answer the following question: Can electromagnetic combined stimulation of the left Dorsolateral prefrontal lobe(DLPFC) improve the performance of working memory, motor function and cognitively motor dual tasks in stroke patients? What is its mechanism of action? Participants will undergo a combined real or sham electromagnetic stimulation of 20 minutes of tDCS and 40 seconds of TMS once a day for 7 days. Researchers will compare the effects of real stimulation with sham stimulation to see if the real stimulation can bring better results to patients. Clinical evaluations (cognitive and motor scales) and functional Near-Infrared Spectroscopy(fNIRS) were conducted before and after stimulation to record relevant brain activities",[119,27],"Stroke","2026-05-06",{"date":122,"type":38},"2026-05-11",{"date":124,"type":21},"2026-05-01",{"date":126,"type":21},"2027-05-01",{"name":128,"class":45},"Ke Dong, MD",{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":133,"acronym":4,"eligibilityCriteria":134,"healthyVolunteers":11,"sex":17,"minAge":112,"maxAge":113,"enrollmentInfo":135,"targetDuration":4,"studyType":22,"phases":136,"briefSummary":137,"conditions":138,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":139,"startDateStruct":140,"completionDateStruct":141,"leadSponsor":142,"locationsCount":46},"100637039","dual-site-cross-frequency-coupled-transcranial-electrical-stimulation-modulates-working-memory-of-patients-with-post-stroke-cognitive-impairment-100637039","NCT07573501","Dual-site Cross-frequency Coupled Transcranial Electrical Stimulation Modulates Working Memory of Patients With Post-stroke Cognitive Impairment","Inclusion Criteria:\n\n* Meeting the diagnostic criteria for hemorrhagic or ischemic stroke in the Chinese Guidelines for the Prevention and Treatment of Cerebrovascular Diseases(2nd edition), with the first onset, single hemisphere stroke, and confirmed by CT or MRI,course of diease 1-6 months;\n* Age ranging from 30 to 80 years old;\n* Native language is Mandarin or Cantonese;\n* Right-handed;\n* Diagnosed with PSCI by the MoCA scale;\n* Able to cooperate in completing the speech repetition test;\n* Normal hearing.\n\nExclusion Criteria:\n\n* Currently receiving non-invasive brain stimulation treatment;\n* Lesions involving the left DLPFC brain regions;\n* History of epilepsy, mental illness,or other neurological or mental disorders;\n* Any contraindications for transcranial electrical stimulation.",{"count":115,"type":21},[24],"This clinical trial aims to explore the effect of dual-site theta-gamma cross-frequency coupled transcranial alternating current stimulation in the frontal and parietal region on the working memory ability of patients with cognitive impairment after stroke, and to evaluate the safety of this protocol. The main purpose is to answer the following question: Can dual-site cross-frequency coupled tACS in the frontal parietal region improve the performance of working memory and cognitive-motor dual tasks in stroke patients? What is its mechanism of action? Researchers will compare the effects of real cross-frequency coupled stimuli and sham stimuli to see if the real stimuli can bring better results to patients. Participants will receive 40 minutes of real or sham electrical stimulation once a day for 5 consecutive days. Clinical evaluations (cognitive scales) and fNIRS were conducted respectively before and after stimulation to record the relevant brain activities at rest and during cognitive tasks",[119,27],{"date":122,"type":38},{"date":124,"type":21},{"date":126,"type":21},{"name":128,"class":45},{"id":144,"slug":145,"hasResults":11,"nctId":146,"briefTitle":147,"officialTitle":147,"acronym":4,"eligibilityCriteria":148,"healthyVolunteers":16,"sex":17,"minAge":149,"maxAge":150,"enrollmentInfo":151,"targetDuration":4,"studyType":153,"phases":4,"briefSummary":154,"conditions":155,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":46},"100241458","mri-technical-development-and-applications-in-kidney-disease-100241458","NCT02421497","MRI Technical Development and Applications in Kidney Disease","For Specific Aim 1: MRI Technical Development Studies\n\nInclusion Criteria:\n\n1\\. Healthy Volunteer\n\nExclusion Criteria:\n\n1. Ferromagnetic implants\n2. Any foreign metal objects in the body\n3. History of shrapnel or shot gun injury\n4. Cardiac pacemakers\n5. Defibrillator\n6. Neuronal stimulator\n7. Magnetic aneurysm clip\n8. Large tattoos on the abdomen or the brain and neck\n9. Hip replacement\n10. Too large to fit in the magnet (body mass index \\>= 40, approx.)\n11. Severe claustrophobia\n12. Women with pregnancy\n\nFor Specific Aim 2: Pilot Studies with Patients\n\nStudies for CKD\n\nInclusion\n\n1. English- speaking as primary language.\n2. Age 45 years and older\n3. Able to complete an approximately 90 minute cognitive testing battery.\n4. Able to sign the informed consent, or allow a caregiver, relative, surrogate, or witness to sign the informed consent if participant is unable to do so.\n5. GFR \\\u003C 90 ml\u002Fmin\u002F1.73m2\n\nExclusion\n\n1. Acute psychiatric illness that would impede cognitive testing\n2. Active chemical dependence, such as alcohol, narcotics or other drugs\n3. Legally blind or unable to complete cognitive tests due to visual loss or deafness\n4. Dialysis dependent or renal transplant recipient at time of screening or baseline\n5. Chronic obstructive pulmonary disease\n6. Severe CI unable to complete the Modified Mini-Mental State Examination \\[3MSE\\]\n\nStudies for Renal Transplantation\n\nInclusion\n\n1. Able to sign the informed consent, or allow a caregiver, relative, surrogate, or witness to sign the informed consent if participant is unable to do so.\n2. Age 45 years and older\n\nExclusion\n\n1. Not on dialysis due to allograft failure\n2. Chronic obstructive pulmonary disease","18 Years","70 Years",{"count":152,"type":21},180,"OBSERVATIONAL","Magnetic resonance imaging (MRI), as a non-invasive and non-contrast enhanced technique, has the potential to improve patient health care and management. The overall objective of proposed project is to:\n\n1. develop, customize, and optimize anatomic and functional MRI methods,\n2. explore the use of MRI methods to study CKD and evaluate post-transplant kidneys, and\n3. investigate the potential of MRI in the diagnosis, prognosis, and monitoring of the progression of renal dysfunction.\n\nIn addition to direct studies of the kidney, brain MRI studies will also be performed to identify the cerebrovascular and cognitive effects of chronic renal function deficiency and medical treatment (e.g. hemodialysis and immunosuppression). The brain and kidneys have similar vascular bed, and both are susceptible to vascular injury, which provides the pathological basis for the widely recognized association of reduced renal function with prevalent cerebrovascular diseases (CVDs) and cognitive impairment (CI). The MRI methods in the brain will be applied to explore the origins for widely observed CVDs and prevalent cognitive impairment (CI) in kidney disease patients.",[156,157,158,27],"Chronic Kidney Diseases","Kidney Transplantation","Dialysis","2026-04-09",{"date":161,"type":38},"2026-04-13",{"date":163,"type":21},"2028-06-30",{"date":165,"type":21},"2029-12-30",{"name":167,"class":45},"University of Minnesota",{"id":169,"slug":170,"hasResults":11,"nctId":171,"briefTitle":172,"officialTitle":172,"acronym":173,"eligibilityCriteria":174,"healthyVolunteers":11,"sex":17,"minAge":149,"maxAge":4,"enrollmentInfo":175,"targetDuration":4,"studyType":153,"phases":4,"briefSummary":177,"conditions":178,"keywords":180,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":192,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":198,"locationsCount":46},"100628990","influence-of-individual-traits-on-adaptation-processes-in-individuals-with-alcohol-use-disorder-100628990","NCT07468825","Influence of Individual Traits on Adaptation Processes in Individuals With Alcohol Use Disorder","TIPA","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* Patients receiving care for Alcohol Use Disorder at the Psychiatry and Addiction Unit of Paul Brousse Hospital\n* No objection to participation in the study\n\nExclusion Criteria:\n\n* Diagnosed neurological disorder\n* Patient covered by State Medical Assistance (AME)\n* Individuals under legal protection measures (guardianship, curatorship, or legal safeguard)\n* Individuals deprived of liberty by judicial or administrative decision\n* Pregnant or breastfeeding women\n* Psychiatric disorders that could compromise proper study participation (excluding Alcohol Use Disorder)",{"count":176,"type":21},30,"Alcohol Use Disorder (AUD) is a chronic condition that affects behavior, decision-making, and the ability to adapt to changing situations. While many studies have examined AUD from medical and social perspectives, less is known about how individual psychological traits influence the way people with AUD respond to uncertainty and adapt their behavior.\n\nThis study aims to better understand how personal characteristics such as anxiety, self-esteem, sensitivity to reward and punishment, perfectionism, and cognitive abilities may influence adaptation processes in individuals with AUD.\n\nParticipants receiving usual care at Paul Brousse Hospital will be invited to take part in a single experimental session lasting about 45 minutes. During this session, they will complete:\n\n* A computerized learning task in which they respond to visual stimuli and receive feedback on their performance\n* Standardized questionnaires assessing psychological traits and cognitive functioning\n\nThe learning task is designed to evaluate how participants adjust their behavior when the rules of the task change unexpectedly. Researchers will measure how performance changes in response to uncertainty and examine how these changes relate to individual psychological characteristics.\n\nThis research does not modify participants' medical care and involves no medication or invasive procedures.\n\nBy improving understanding of the cognitive and behavioral mechanisms involved in Alcohol Use Disorder, the study may help advance scientific knowledge about how individuals adapt to uncertainty and inform future research in addiction and mental health.",[179,27],"Alcohol Use Disorder",[179,181,182,183,184,185,186,187,188,189,190],"Addictive Behaviors","Decision Making","Cognitive Adaptation","Behavioral Flexibility","Uncertainty Processing","Exploration-Exploitation Tradeoff","Neurocognitive Processes","Personality Traits","Psychological Assessment","Computerized Cognitive Task","2026-03-09",{"date":193,"type":38},"2026-03-13",{"date":195,"type":21},"2026-04-01",{"date":197,"type":21},"2027-04-01",{"name":199,"class":45},"Assistance Publique - Hôpitaux de Paris",{"id":201,"slug":202,"hasResults":11,"nctId":203,"briefTitle":204,"officialTitle":205,"acronym":4,"eligibilityCriteria":206,"healthyVolunteers":16,"sex":17,"minAge":207,"maxAge":208,"enrollmentInfo":209,"targetDuration":4,"studyType":153,"phases":4,"briefSummary":211,"conditions":212,"keywords":215,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":221,"lastUpdatePostDateStruct":222,"startDateStruct":224,"completionDateStruct":226,"leadSponsor":228,"locationsCount":230},"100621655","westlake-aging-cohort-weac-100621655","NCT07373444","Westlake Aging Cohort (WeAC)","Westlake Aging Cohort","Inclusion Criteria:\n\n1. Age between 55 and 90 years (inclusive) at baseline.\n2. Availability of a companion capable of providing independent functional assessments and fluent in Chinese.\n3. Willingness and ability to regularly complete required surveys and physical examinations as per study protocol.\n4. MMSE scores were required to be 24-30 (inclusive) for healthy controls and MCI; and 20-24 (inclusive) for AD and DLB\u002FPDD patients.\n5. Healthy controls: CDR = 0, memory box = 0. MCI: CDR = 0.5, memory box ≥ 0.5. AD: CDR = 0.5 or 1. The DLB\u002FPDD meets the core features of diagnosis.\n6. Healthy controls exhibit no significant cognitive or functional decline. Patients with MCI have objective cognitive impairment not sufficient for an AD diagnosis. AD patients fulfill the NINCDS-ADRDA criteria. DLB\u002FPDD patients meet their respective international consensus diagnostic criteria. Other neurodegenerative diseases meet the diagnostic criteria.\n\nExclusion Criteria:\n\n1. Participants with major medical or neuropsychiatric conditions unrelated to the study purposes were excluded. These included, but were not limited to, psychiatric disorders, cancer, infectious diseases, structural brain abnormalities, and epilepsy.\n2. Current use of psychoactive medications or any other drugs that may affect the study.\n3. Participants with cardiac pacemakers, artificial heart valves, or metallic implants in the eyes, skin, or any other part of the body.\n4. Participants with any other diseases that may affect the study.","55 Years","90 Years",{"count":210,"type":21},2800,"The Westlake Ageing Cohort (WeAC) is a longitudinal cohort study conducted in Hangzhou, Zhejiang Province, China. The investigators aim to enroll 2,800 participants aged 55 years and older for long-term follow-up. The population will include individuals with neurodegenerative diseases or those at the prodromal stage of cognitive impairment, as well as healthy middle-aged and older adults serving as controls. The investigators will collect their sociodemographic, dietary, lifestyle, clinical, and neuroimaging data, as well as biological samples.",[66,213,27,214],"Cognition Improvement","Cognition",[216,217,218,219,220],"aging","cognition","gut microbiota","multi-omics","brain","2026-01-19",{"date":223,"type":38},"2026-01-28",{"date":225,"type":21},"2026-01-01",{"date":227,"type":21},"2031-12-31",{"name":229,"class":45},"Westlake University",2,{"id":232,"slug":233,"hasResults":11,"nctId":234,"briefTitle":235,"officialTitle":236,"acronym":4,"eligibilityCriteria":237,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":208,"enrollmentInfo":238,"targetDuration":4,"studyType":22,"phases":240,"briefSummary":241,"conditions":242,"keywords":245,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":248,"lastUpdatePostDateStruct":249,"startDateStruct":251,"completionDateStruct":253,"leadSponsor":255,"locationsCount":4},"100579940","supplementation-of-inulin--l-acidophilus-in-elders-with-t2dm-100579940","NCT06830824","Supplementation of Inulin + L. Acidophilus in Elders with T2DM","Effect of Supplementation of a Symbiotic (Inulin + Lactobacillus Acidophilus) on Cognitive Impairment in Older Adults with Type 2 Diabetes Mellitus","Inclusion Criteria:\n\n* Patients between 60-90 years of age with a diagnosis of DM2 who present some degree of cognitive impairment, assessed with the scales.\n* Patients who sign the informed consent form.\n\nExclusion Criteria:\n\n* Patients who in the development of the study present comorbidities that influence cognitive impairment.\n* Patients who present adverse effects to supplementation.\n* Patients who decide to abandon the study or withdraw informed consent. - -Patients who do not take the symbiotic for 3 consecutive doses.",{"count":239,"type":21},48,[24],"This study investigates the effects of a symbotic supplement (Inulin + Lactobacillus acidophilus) on cognitive impairment in older adults with type 2 diabetes mellitus (T2DM). Diabetes is a chronic disease characterized by insulin deficiency or resistance, leading to hyperglycemia and long-term complications, including cognitive decline. Cognitive impairment in T2DM patients is linked to oxidative stress, neuroinflammation, and disrupted insulin signaling in the brain.\n\nThe gut-brain axis plays a crucial role in cognition, with gut microbiota influencing neuroinflammatory processes. Dysbiosis, common in T2DM, exacerbates cognitive decline. Probiotics like Lactobacillus acidophilus and prebiotics like inulin can restore gut microbiota balance, reduce inflammation, and promote brain-derived neurotrophic factor (BDNF) production, improving cognitive function.\n\nThis randomized, crossover clinical trial will enroll 24 patients aged 50-65 with T2DM and mild cognitive impairment. Participants will be divided into control and experimental groups, with an 8-week intervention phase followed by a crossover. The experimental group will receive 8g of inulin and L. acidophilus daily, while the control group will receive a placebo. Cognitive assessments (MMSE, MoCA), PET-CT imaging, gut microbiota sequencing, and butyrate measurements will evaluate the intervention's effects.\n\nThe study aims to determine whether symbiotic supplementation can improve cognitive function and metabolic brain activity in T2DM patients. If successful, it may offer an accessible, non-pharmacological approach to mitigating diabetes-related cognitive decline. The research is funded by the Universidad Anáhuac Health Sciences Research Center and international diabetes research organizations.",[243,244,27],"Diabetes Mellitus","Microbiome",[243,246,247],"Supplementation","Cognitive impairment","2025-02-17",{"date":250,"type":38},"2025-02-19",{"date":252,"type":21},"2025-03",{"date":254,"type":21},"2025-12",{"name":256,"class":45},"Anahuac University",{"id":258,"slug":259,"hasResults":11,"nctId":260,"briefTitle":261,"officialTitle":261,"acronym":262,"eligibilityCriteria":263,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":264,"targetDuration":4,"studyType":153,"phases":4,"briefSummary":266,"conditions":267,"keywords":4,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":273,"lastUpdatePostDateStruct":274,"startDateStruct":276,"completionDateStruct":278,"leadSponsor":279,"locationsCount":46},"100313467","development-of-a-prediction-model-for-delirium-after-cardiac-surgery-using-a-novel-self-administered-preoperative-cognitive-assessment-tool-100313467","NCT03360838","Development of a Prediction Model for Delirium After Cardiac Surgery Using a Novel Self-Administered Preoperative Cognitive Assessment Tool","CogCheck-Valid","Inclusion Criteria:\n\n* Elective cardiac surgery\n* Age ≥60 years\n* Good knowledge of the German language\n* Written informed consent\n\nExclusion Criteria:\n\n* Emergency surgery\n* Medical instability limiting preoperative assessment\n* Surgical procedures without the use of cardiopulmonary bypass\n* Procedures involving deep hypothermic circulatory arrest\n* Concurrent carotid surgical procedures\n* Participation in an interventional trial with POD or POCD as primary endpoint",{"count":265,"type":21},475,"This observational cohort study is designed to validate the CogCheck application as a risk prediction tool for postoperative delirium in patients undergoing cardiac surgery.",[268,269,270,271,27,272],"Postoperative Delirium","Postoperative Cognitive Dysfunction","Cognitive Decline","Cognitive Impairment","Cardiac Surgery","2025-01-22",{"date":275,"type":38},"2025-01-27",{"date":277,"type":38},"2018-04-16",{"date":254,"type":21},{"name":280,"class":45},"University Hospital, Basel, Switzerland"]